Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSTAR Lung: Cobolimab + Dostarlimab + Docetaxel in Advanced NSCLC
NCT04655976Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2020
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of cobolimab in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Dec 2020; status: active, not recruiting.
02
Drugs
cobolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04655976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655976.